Elsevier

Clinical Therapeutics

Volume 30, Issue 12, December 2008, Pages 2402-2406
Clinical Therapeutics

Prolonged intrahepatic cholestasis after exposure to loxoprofen

https://doi.org/10.1016/j.clinthera.2008.12.012Get rights and content

Abstract

Objective: The objective of this report was to describe a case of prolonged intrahepatic cholestasis likely associated with the use of loxoprofen, a phenylpropionate NSAID.

Methods: A 36-year-old female patient was transferred to Gunma University Hospital, Maebashi, Japan, with progressive pruritus and jaundice that developed after 5-day treatment with 120 mg/d of loxoprofen (maximum recommended dose, 180 mg/d) for menstrual pain. Liver function tests found the following concentrations: total bilirubin, 27.5 mg/dL (normal [nl] range, 0.3–1.2 mg/dL); aspartate aminotransferase, 151 IU/L (nl, 13–33 IU/L); alkaine aminotransferase, 470 IU/L (nl, 8–42 IU/L); alkaline phosphatase, 1082 IU/L (n1, 115–359 IUAL); and γ-glutamyl transpeptidase, 795 IU/L (nl, 10–47 IU/L) indicative of intrahepatic cholestasis. No use of alcohol or other drugs or herbal products was reported. The patient had a history of elevated hepatic enzymes of unknown origin following the use of mefenamic acid. The patient was prescribed ursodeoxycholic acid 3 weeks after the onset of symptoms of intrahepatic cholestasis. Thereafter, due to progressive cholestasis, an IV pulse of methylprednisolone (1000 mg/d) and the herbal product Inchin-ko-to (TJ-135) were administered. Plasma bilirubin adsorption (PA) and plasma exchange (PE) were performed.

Results: Following treatment with PA and PE for 3 weeks with administration of methylprednisolone and Inchin-ko-to, signs and symptoms of intrahepatic cholestasis began to resolve (3.5 months after the onset); they were completely resolved 8 months after the initial episode. A Naranjo scale score of 6 suggested that loxoprofen was likely the cause of the prolonged cholestasis in this patient.

Conclusion: Based on the Naranjo score, this case of prolonged intrahepatic cholestasis in a young woman was likely associated with loxoprofen use.

References (21)

There are more references available in the full text version of this article.

Cited by (5)

  • Anti-inflammatory and antipyretic analgesics and drugs used in gout

    2011, Side Effects of Drugs Annual
    Citation Excerpt :

    Based on the timing of the collapse after ketorolac tromethamine injection, her death was attributed to an adverse reaction to ketorolac tromethamine, resulting in acute bronchospasm and cardiac arrest. A 36-year-old woman developed progressive intrahepatic cholestasis after a 5-day course of loxoprofen 180 mg/day for menstrual pain [47A]. Celecoxib-associated anaphylaxis has been described in a patient who had previously tolerated it [48A].

  • Inchinkoto and jaundice

    2016, Methods in Pharmacology and Toxicology
View full text